Skip to main content
. 2024 Jan 10;22:27. doi: 10.1186/s12964-023-01406-8

Fig. 1.

Fig. 1

CLDN18.2 Expression Correlates with Clinical Staging in Gastric Cancer. a. The chi-square test was used to compare the CLDN18.2 H-score > 40 and H-score < 40 in different TNM stages in our cohort. b. The comparison of CLDN18.2 H-score in different TNM stages in our cohort, student t-test was utilized. c-d. The comparison of CLDN18.2 H-score in different clinicopathologic features in our cohort was performed. e. The overall survival of patients was based on CLDN18.2 expression in our cohort, which was evaluated using the log-rank test. The statistical significance was denoted as * P < 0.05, ** P < 0.01, *** P < 0.001, and not significant (ns)